WHO ICTRP trial
1 day vs 3 days of terlipressin therapy in cirrhosis patients with variceal…
CTRI/2019/10/021771 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2019/10/021771 |
|---|---|
| Public title | 1 day vs 3 days of terlipressin therapy in cirrhosis patients with variceal bleeding |
| Scientific title | Comparison of 1-day vs. 3-day intravenous terlipressin in patients with acute variceal bleeding: open-label randomized control trial. - TER1vs3 |
| Primary sponsor | Dr Shalimar |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | India |
| Conditions | Health Condition 1: - Health Condition 2: K74- Fibrosis and cirrhosis of liver |
| Interventions | Intervention1: Terlipressin-3d arm: Patients will receive intravenous bolus terlipressin for 1 mg every 4 hours from the time of admission, and it will continue for 72 hours. Control Intervention1: Terlipressin-1d arm: Patients will receive… |
| Registration date | Oct 23, 2019 |
| Target size | 200 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: